Showing 2191-2200 of 8626 results for "".
Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaRevance Data, AD Updates, FDA Actions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-revance-data-ad-updates-fda-actions/18463/A US District Court judge blocks Stratus Pharmaceuticals of Miami and Sonar Products of Carlstadt, NJ from selling substandard dermatological products. Newly identified mutations in a gene called CARD11 may lead to atopic dermatitis. Surprising new evidence suggests atopic dermatitis is associated wWhy Your Dermatology Practice Should Be On Instagram
https://practicaldermatology.com/topics/practice-management/dermpracticeinstagram/18473/Instagram is different from most social networks. And it's growing quickly with skyrocketing mobile technology use. It's a marketing opportunity for dermatologists, especially those interested in cosmetic procedures. Learn how to use Instagram for your practice marketing and outreach in this Ekwa.coWhat's Old Is New
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/old-new-2017/18512/Besides new fillers and better device-based combinations, Joel L. Cohen, MD says that 2017 will bring new data on some existing interventions that may improve aesthetic procedures. Watch the video memo now.Neuromodulators in Medical Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neuromodulators-in-medical-dermatology/18520/Physicians are exploring the effects of botulinum toxins on several medical dermatology conditions. Erin Gilbert, MD talks to Joel Cohen, MD about her experience treating rosacea, and discusses the need for better randomized trials to explore treatment options.Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhofade-approved-sun-leaves-acne-behind-radiesse-turns-10/18552/The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking upThe Importance of Link Building for your Practice
https://practicaldermatology.com/topics/practice-management/the-importance-of-link-building-for-your-practice/18554/The link-building discussion is sometimes confusing, but link building is never a waste of time. They add value to content and build credibility of content. Links from quality sources promote content, boost traffic, and build visibility. This Ekwa.com Ekwa educational video explains why link-buildinHow to Optimize Twitter for your Practice
https://practicaldermatology.com/topics/practice-management/how-to-optimize-twitter-for-your-practice/18558/Twitter offers practices numerous opportunities to derive great business value. It's essential to identify specific conversations, and then use the information to optimize marketing in targeted areas. This Ekwa.com Marketing Educational video explains how dermatology practices can use Twitter to effLasers in Acne: Expanding the Options
https://practicaldermatology.com/topics/general-topics/lasers-in-acne-expanding-the-options/18745/By Abigail Waldman, MD and Seemal R. Desai, MDThe Nd-YAG (1064nm) laser can be used for acne—including cystic acne—and acne scarring. Dr. Waldman discusses the AAD's first-ever hands-on laser session and the role of the Nd-YAG laser in patient care.Risk In Your Portfolio
https://practicaldermatology.com/topics/practice-management/risk-in-your-portfolio/18588/Do you know your risk score? Physicians must understand their personal tolerance for risk as well as the level of risk in their current portfolios. If there is a mismatch, how do you rectify the disconnect. Bob Peelman, CFP, of OJM Group, explains. ABOUT THE AUTHOR